These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 6226084)

  • 1. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
    Feddersen C
    Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the degradation of fibrinogen by proteolytic enzymes from the larvae of Lanomia achelous (Cramer).
    Arocha-Piñango CL; Perales J; Carvajal Z
    Thromb Haemost; 1981 Jun; 45(3):233-6. PubMed ID: 6456570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on high molecular weight fibrinogen/fibrin complex (HMWFC) (author's transl)].
    Suzuki S; Matsui N
    Rinsho Ketsueki; 1979 Aug; 20(8):901-9. PubMed ID: 502006
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comprehensive laboratory evaluation of changes in the fibrinogen molecule in the diagnosis of acquired coagulopathy conditions].
    Siatkovskiĭ VA; Azarova LA; Vasilenko PL
    Lab Delo; 1989; (8):45-8. PubMed ID: 2477628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The fibrinogen-fibrin-fibrinolysis system in rheumatoid arthritis].
    Belitskaia GA; Palienko IA; Shevchenko LI; Fedorova NE
    Vrach Delo; 1989 Jan; (1):47-50. PubMed ID: 2718445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of fibrin-fibrinogenolysis on the determination of the fibrinogen content and fibrin-fibrinogen degradation products (FDP) by means of the fibrin polymerization time (FPT test)].
    Vorlová Z; Dyr IE
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):967-70. PubMed ID: 94893
    [No Abstract]   [Full Text] [Related]  

  • 8. Degradation of fibrinogen by proteolytic enzymes. II. Effect of the products on coagulation.
    Miller SP; Sanchez-Avalos J
    Thromb Diath Haemorrh; 1968 Nov; 20(1):15-30. PubMed ID: 4236936
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of lytic effect on fibrin of immobilized heparin in complex with plasma proteins].
    Platé NA; Valuev LI; Gumirova FKh; Maklakova IA
    Vopr Med Khim; 1982; 28(5):19-23. PubMed ID: 6217639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
    Arnesen H
    J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
    [No Abstract]   [Full Text] [Related]  

  • 11. [Soluble fibrin monomer complexes in thromboembolism].
    Gryglik J
    Przegl Lek; 1982 Sep; 39(8):551-3. PubMed ID: 6753042
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fibrinolysis].
    Levy G; Michault A; Jamet M
    Ann Anesthesiol Fr; 1978; 19(8):703-8. PubMed ID: 31114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-fibrin degradation products.
    Kwaan HC
    Ann Clin Lab Sci; 1980; 10(3):234-7. PubMed ID: 7396389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural considerations of plasmic degradation of fibrinogen.
    Marder VJ; Budzynski AZ
    Pathol Biol (Paris); 1974 Nov; 22 suppl():43-6. PubMed ID: 4283397
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mechanism of fibrinolysis (review of the literature)].
    Kovalenko AN
    Vrach Delo; 1983 Jan; (1):10-5. PubMed ID: 6223445
    [No Abstract]   [Full Text] [Related]  

  • 16. [An analysis of a disorder in the fibrin-forming phase in virtually healthy middle-aged and elderly subjects by using the ancistron test].
    Platonova TN; Sushko OO; Lukinova NI; Solovĭov DA
    Fiziol Zh (1994); 1994; 40(3-4):63-70. PubMed ID: 7621957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
    Hawiger J; Niewiarowski S; Gurewich V; Thomas DP
    J Lab Clin Med; 1970 Jan; 75(1):93-108. PubMed ID: 4243578
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changes in the content of finbrinolysis activating and inhibiting factors and of fibrinogen in patients with thrombosis and prethrombotic conditions].
    Andreenko GV
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(2):195-7. PubMed ID: 50983
    [No Abstract]   [Full Text] [Related]  

  • 19. Unreliability in the estimation of the molecular weight of fibrinogen degradation products (FDPs) by polyacrylamide/sodium dodecyl sulphate electrophoresis (SDS/PAGE).
    Arocha-Piñango CL; Perales J; Carvajal Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(5):737-41. PubMed ID: 2416650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new quick and sensitive method for analysis of fibrin metabolism products in serum--theoretic and practical meaning].
    Gormsen J
    Nord Med; 1970 Jul; 84(31):999. PubMed ID: 4247659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.